KRAS and colorectal cancer: Finally, it was recently demonstrated that inflammatory micro-environment could account for Trametinib resistance in PDO cultures from KRAS-mutant colorectal tumors and increased expression of this panel of inflammatory genes was significantly correlated with colorectal cancer overall survival in TCGA database69.